Safe Delivery Pharmaceutical intermediates Lower Price GMP Manufacturer INS 365 CAS 211427-08-6 Diquafosol tetrasodium CAS NO.211427-08-6
- FOB Price: USD: 0.02-0.03 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
Top(1-1000)GramTop(1000-2000)Gram
- Product Details
Keywords
- Diquafosol tetrasodium
- GMP Manufacturer INS 365
- CAS 211427-08-6
Quick Details
- ProName: Safe Delivery Pharmaceutical intermedi...
- CasNo: 211427-08-6
- Molecular Formula: C18H27N4NaO23P4
- Appearance: White powder
- Application: 1. Diquafosol tetrasodium eye drops fo...
- DeliveryTime: 3-7days
- PackAge: bag or barrel or drum
- Port: Shanghai or Shenzhen or Qingdao
- ProductionCapacity: 6000 Metric Ton/Day
- Purity: 99%+
- Storage: Store at room temperature
- Transportation: by express or air or sea
- LimitNum: 1 Gram
- Moisture Content: <0.001%
- Impurity: <0.001%
- Assay: 99%+
- Shelf Life: 2 years
- Appearance: White Powder
Superiority
English name: INS 365
CAS number: 211427-08-6
Molecular formula: C18H27N4NaO23P4
Molecular weight: 814.3
EINECS Number: 253-874-2
Diquafosol Tetrasodium (Diquafosol Tetrasodium) chemical name is P1,P4-bis(uridine 5'-tetraphosphate) sodium, jointly developed by Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceutical Co., Ltd., and launched in Japan in 2010 , traded under the trade name Diquas, and diquafosol tetrasodium eye drops had sales of about $100 million in 2017. Diquafosol tetrasodium eye drops are the first P2Y2 receptor agonist eye drops approved in the world. It acts on the P2Y2 receptors on the conjunctival epithelium and goblet cell membrane, and increases the concentration of calcium ions in cells to promote The secretion of water and mucin, thereby improving the symptoms of dry eye disease, so that the tear film is closer to the normal state. In addition, diquafosol tetrasodium eye drops are expected to be developed as expectorants with expectoration-inducing action or as a drug for treating pneumonia.
1. Diquafosol tetrasodium eye drops for watery tear-deficient dry eye can improve the visual quality of patients with tear-deficient dry eye, while enhancing tear film stability and reducing corneal epithelial damage.
2. Short tear film breakup time dry eye The clinical manifestations of short tear film breakup time (BUT) and dry eye symptoms are short tear film breakup time (BUT), no ocular surface damage and tear deficiency. After 2 and 4 weeks of diquafosol tetrasodium eye drops, BUT was significantly prolonged (P < 0.05) in patients with BUT-shortened dry eye, and fluorescein staining score, Schirmer test score and intraocular scattering were improved (all is P<0.001).
3. Obstructive Meibomian Gland Dysfunction Obstructive Meibomian gland dysfunction is a major cause of lipid-deficient dry eye and evaporative dry eye, and may also lead to reduced tear film stability. At present, P2Y2 receptors have been confirmed to exist in meibomian glands. Patients with obstructive meibomian gland dysfunction were treated with 30 g·L-1 diquafosol tetrasodium eye solution for 4 months, and their ocular symptoms, eyelid margin abnormalities, BUT, TMH and eye staining scores were significantly improved.
4. Dry eye related to anterior segment surgery Dry eye is one of the common complications after LASIK. The specific mechanism is not clear, and for patients with dry eye before surgery, the postoperative symptoms will be further aggravated, which will affect the surgery. curative effect. For dry eye patients after LASIK, some scholars found that the uncorrected distance visual acuity of the combined application group of 30g·L-1 diquafosol tetrasodium eye drops and 3g·L-1 sodium hyaluronate eye drops was higher than 3g·L -1 Sodium hyaluronate eye drops group.
5. Contact lens wearers have found that wearing contact lenses can significantly reduce TMH, and TMH can be significantly improved temporarily after using 30g·L-1 diquafosol tetrasodium eye drops.
6. Video terminal syndrome Due to the lack of relevant research at this stage, it is tentatively believed that 30g·L-1 diquafosol tetrasodium may be effective for patients with video terminal syndrome.
Details
Wuhan Kanal Technology Co., Ltd. founded in 2010,it is a large manufacturer of fine Pharmaceutical& Chemical & Cosmetic materials that integrates R&D, production and sales together. Our Kanal company is established under the support of the Wuhan city government, so Kanal has large advantages in enterprise credit, finance security, product quality control, and cargo export.Kanal locates in the national new materials industry park of Wuhan city and is awarded the title of high-tech corporation.
Wuhan Kanal has its own R&D and development laboratory. We Kanal set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience and technology in organic synthesis development. It owns almost 15 acre and more than 280 workers.
An ISO 9001 & GMP qualified company, we are mainly specialized in producing high quality but low price Pharmaceutical intermediates, APIs and other fine chemicals & cosmetics products which related to human and animals medicines as well as additives in gas &oil field, almost half of the goods are for exporting. What's more, we provide the OEM (customize) manufactures, if you can't find materials from the world, then tell us, we will research and produce in our high-tech equipmented laboratory. We are dedicated to satisfying our customers with our products and services.
1. We has 11 years' exporting experience in active pharmaceutical ingredient products.
Our professional and thoughtful after-sales service eliminates your worries.
2.We can provide you with ten thousands of products of different levels.
3. We offer convenient one-station purchasing service.
(1)Any inquiries will be replied within 12 hours.
(2)Dedication to quality, supply & service.
(3)Strictly on selecting raw materials.
(4)Reasonable & competitive price, fast lead time.
Our company is based on the optical valley biological city,making full use of the park policy advantages, focusing on the research and development of biological medicine.
The pharmaceutical intermediates are mainly applied to anti-cancer, anti-depression, cardiovascular, diabetes and other new medicine. The chemical intermediates mainly refer to heterocyclics and OLED intermediates.Our factory produce new fine chemical materials which are mainly used in water treatment, bactericidal and anti-corrosion, dyes, electronic materials and other industry fields.
Wuhan Kanal has export & import license, and hazard chemical sales license. The products are exported to America, Brazil, South Korea, Japan, Taiwan, Malaysia, Thailand, Indonesia, Europe union and other countries or regions.
Under rich experiences and excellent international reputation, the company becomes a quite influential enterprise in China's API field. Wuhan Kanal sincerely look forward to establishing long good cooperation with our customers from all over the world.